AMRX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AM

Mkt Cap

$6.68B

Volume

1.64M

Next Earnings

October 29th

Loading chart

AM

AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock

AMRX

Pay with—

Available Balance0.00

AM

Mkt Cap

$6.70B

Volume

1.64M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?Amneal Pharmaceuticals shares surged 8.6% following completion of its Kashiv BioSciences acquisition, creating an integrated biosimilars platform. However, consensus EPS estimates were revised 23.1% lower over the past month, which could limit future gains. Ionis Pharmaceuticals declined 5.1% with unchanged negative EPS expectations.Zacks Investment Research · Sep 17, 2026

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month LowWith consumer confidence hitting its lowest level since January due to inflation concerns and labor market uncertainty, five defensive stocks from consumer staples, healthcare, and utilities sectors are recommended: COCO, DAR, CNC, EXC, and AMRX. These stocks offer upside potential with strong earnings growth estimates and improved analyst consensus over the past 60 days.Zacks Investment Research · Aug 27, 2026

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and PresentationsAmneal Pharmaceuticals received FDA approval for additional strengths and vial presentations of iohexol injection (350 mg iodine/mL and 300 mg iodine/mL), with planned Q3 2026 launch. The expanded portfolio is expected to address the majority of U.S. iohexol injection market demand, which generated approximately $706 million in annual sales as of May 2026.GlobeNewswire Inc. · Jul 17, 2026

IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsightDelveInsight's report analyzes the IgE receptor antagonists pipeline with 12+ companies developing therapies for allergic diseases. ADL-018 by Amneal/Kashiv leads in registration stage, while LP-003 by LongBio shows superior Phase II efficacy compared to omalizumab. The market is becoming increasingly competitive with focus on clinical differentiation and speed to market, particularly in China.GlobeNewswire Inc. · Jun 4, 2026

Why Is Amneal Pharmaceuticals Stock Gaining Today?Amneal Pharmaceuticals (AMRX) shares rose 3.76% in premarket trading after announcing a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. The acquisition aims to establish Amneal as a fully integrated global biosimilar platform, positioning it to capitalize on a projected $300 billion global biologics loss-of-exclusivity opportunity. The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.Benzinga · Apr 22, 2026

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.Amneal Pharmaceuticals announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol on April 14, 2026. These are the company's first two metered-dose inhalation (MDI) product launches, marking entry into the complex inhalation category. The products target large markets worth approximately $1.5 billion and $321 million respectively, manufactured at Amneal's dedicated inhalation facility in Ireland.GlobeNewswire Inc. · Apr 14, 2026

Accessible Health Platforms Gain Scale Across $6T Health and Wellness MarketThe global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.Benzinga · Feb 13, 2026

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600S&P Dow Jones Indices announced index changes effective January 30 and February 2, 2026. TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT will be promoted to the S&P MidCap 400, while Amneal Pharmaceuticals, Apellis Pharmaceuticals, and LegalZoom.com will join the S&P SmallCap 600. These changes follow several pending M&A transactions and corporate actions.Benzinga · Jan 27, 2026

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s DiseaseAmneal Pharmaceuticals reported promising interim results from its ELEVATE-PD study for CREXONT, a new extended-release Parkinson's disease treatment. The study showed significant improvements in patient 'Good On' time, reduced 'Off' time, and enhanced motor symptom control across 55 patients.GlobeNewswire Inc. · Dec 5, 2025

Amneal to Participate in Upcoming Investor ConferencesAmneal Pharmaceuticals executives Chirag Patel and Tasos Konidaris will participate in two upcoming healthcare investor conferences in December 2025 and January 2026, presenting the company's strategic outlook.GlobeNewswire Inc. · Dec 2, 2025

to start trading

AM

AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock

AMRX

Pay with—

Available Balance0.00

Your PositionYou don't own any AMRX yet.

Related Tickers

Earnings